IQVIA (IQV) Expected to Announce Quarterly Earnings on Thursday

IQVIA (NYSE:IQV) is expected to issue its Q4 2025 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $3.40 per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:00 AM ET.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.84 EPS. On average, analysts expect IQVIA to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

IQVIA Trading Down 0.6%

Shares of IQVIA stock opened at $239.67 on Thursday. The company’s fifty day simple moving average is $230.48 and its 200-day simple moving average is $207.51. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA has a 1-year low of $134.65 and a 1-year high of $247.04. The stock has a market capitalization of $40.82 billion, a PE ratio of 32.88, a P/E/G ratio of 2.45 and a beta of 1.36.

Analysts Set New Price Targets

Several analysts have commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. UBS Group lifted their price target on shares of IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Truist Financial boosted their price objective on shares of IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Finally, TD Cowen boosted their price objective on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $251.06.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Measured Wealth Private Client Group LLC acquired a new position in shares of IQVIA in the third quarter worth $30,000. Johnson Financial Group Inc. purchased a new position in shares of IQVIA in the 3rd quarter valued at approximately $52,000. Wealth Watch Advisors INC purchased a new stake in shares of IQVIA in the third quarter valued at about $74,000. MUFG Securities EMEA plc acquired a new stake in shares of IQVIA in the 2nd quarter valued at approximately $77,000. Finally, Ancora Advisors LLC lifted its stake in shares of IQVIA by 17.9% in the third quarter. Ancora Advisors LLC now owns 521 shares of the medical research company’s stock valued at $99,000 after purchasing an additional 79 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.